{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:38:13Z","timestamp":1787931493776,"version":"build-2784847793"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Elranatamab, a bispecific antibody targeting B\u2010cell maturation antigen, is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). An exposure\u2013safety analysis was conducted using the data from patients with RRMM across four clinical studies, MagnetisMM\u20101, 2, 3, and 9 (NCT03269136, NCT04798586, NCT04649359, and NCT05014412). The selected safety endpoints included grade \u22653 infections, neutropenia, anemia, and thrombocytopenia. Additionally, the relationship between the elranatamab exposure and dose interruptions and discontinuation events was explored. The results showed no statistically significant relationship between elranatamab exposure and the incidence of these safety events. The flat exposure\u2013safety relationship with the evaluated safety endpoints suggested a similar probability of experiencing these events with the 76\u2010mg once\u2010weekly (QW) regimen compared with lower doses within the efficacious dose range (215\u20131000 \u00b5g\/kg, equivalent to 16\u201376 mg). These data support the use of a full dose of 76 mg QW and do not indicate that selecting a lower dose would significantly mitigate the risk for adverse events. Additionally, these findings support managing elranatamab adverse drug reactions through temporary dose interruption rather than dose reduction.<\/jats:p>","DOI":"10.1002\/jcph.70130","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:09:07Z","timestamp":1765976947000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Elranatamab Exposure\u2013Safety Analysis in Relapsed or Refractory Multiple Myeloma"],"prefix":"10.1002","volume":"66","author":[{"given":"Pooneh","family":"Soltantabar","sequence":"first","affiliation":[{"name":"Oncology Research and Development Pfizer Inc.  San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hibma","sequence":"additional","affiliation":[{"name":"Research and Development Pfizer Inc.  La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Wang","sequence":"additional","affiliation":[{"name":"Oncology Research and Development Pfizer Inc.  San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Conte","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hickman","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9825-5890","authenticated-orcid":false,"given":"Mohamed","family":"Elmeliegy","sequence":"additional","affiliation":[{"name":"Oncology Research and Development Pfizer Inc.  San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21771"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02734"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01697-0"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2011.01067.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0734-z"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010539"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006178"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01793-1"},{"key":"e_1_2_8_14_1","unstructured":"US Food and Drug Administration.FDA grants accelerated approval to elranatamab\u2010bcmm for multiple myeloma. Accessed November 25 2025.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010elranatamab\u2010bcmm\u2010multiple\u2010myeloma#:~:text=On%20August%2014%2C%202023%2C%20the four%20prior%20lines%20of%20therapy%2C"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00159-6"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169971"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02589-w"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02803.x"},{"key":"e_1_2_8_20_1","unstructured":"HibmaJE ElmeliegyM KingLE McCushF WangD WilliamsJH.Population pharmacokinetic analysis of elranatamab in patients with multiple myeloma. Presented at: PAGE Meeting; June 27\u201030 2023; A Coru\u00f1a Spain. Abstract 10648."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01933-X"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00283-0"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14662"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13049"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01904-3"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004563214541969"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-019-1288-7"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hym033"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27338"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13074"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35107"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01043-5"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011658"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162859"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8041"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01168-y"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70130","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.70130","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:43:25Z","timestamp":1787564605000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/jcph.70130"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70130","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"2025-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70130"}}